A clinical case of cardioprotective therapy with exogenous phosphocreatine during chemotherapy and anti HER2-neu therapy in a patient with breast cancer
The authors describe a clinical observation of cardiotoxicity of anticancer targeted therapy in a young patient with HER2neu-positive breast cancer. The results of instrumental examinations demonstrating manifestations of cardiotoxicity are presented. The development of cardiovascular side effects a...
Saved in:
Main Authors: | Andrey L. Pylev (Author), Vyacheslav A. Lisovoy (Author), Olga S. Kozlova (Author) |
---|---|
Format: | Book |
Published: |
LLC "MEDIAFORMAT",
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The epidemiology of Her-2/ neu and P53 in breast cancer
by: Bernstein Jonine L., et al.
Published: (1999) -
Fusogenic Liposomes for the Intracellular Delivery of Phosphocreatine
by: Okhil K. Nag, et al.
Published: (2024) -
Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer
by: Tyler Keay, et al.
Published: (2013) -
ADJUVANT CHEMOTHERAPY OF PRIMARY OPERABLE LUMINAL B BREAST CANCER WITHOUT OVEREXPRESSION OF HER2/NEU IN POSTMENOPAUSAL WOMEN: YES OR NO?
by: Yu. S. Shatova, et al.
Published: (2017) -
Her-2 neu negative lipid rich breast carcinoma in an immunocompromised patient
by: Deepika Sirohi, M.D, et al.
Published: (2015)